In last trading session, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) saw 12.83 million shares changing hands with its beta currently measuring 0.87. Company’s recent per share price level of $7.16 trading at -$0.27 or -3.63% at ring of the bell on the day assigns it a market valuation of $2.80B. That closing price of RXRX’s stock is at a discount of -119.83% from its 52-week high price of $15.74 and is indicating a premium of 21.79% from its 52-week low price of $5.60. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 17.79 million shares which gives us an average trading volume of 13.95 million if we extend that period to 3-months.

For Recursion Pharmaceuticals Inc (RXRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.43. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.42 in the current quarter.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information

Upright in the red during last session for losing -3.63%, in the last five days RXRX remained trading in the red while hitting it’s week-highest on Friday, 01/24/25 when the stock touched $7.16 price level, adding 13.32% to its value on the day. Recursion Pharmaceuticals Inc’s shares saw a change of 5.92% in year-to-date performance and have moved -4.41% in past 5-day. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) showed a performance of -6.53% in past 30-days. Number of shares sold short was 67.86 million shares which calculate 4.15 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 11 to the stock, which implies a rise of 34.91% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 12. It follows that stock’s current price would jump 16.2% in reaching the projected high whereas dropping to the targeted low would mean a gain of 16.2% for stock’s current value.

Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts

Statistics highlight that Recursion Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -12.58% of value to its shares in past 6 months, showing an annual growth rate of 0.63% while that of industry is 17.30. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 52.11% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 19.04M for the same. And 3 analysts are in estimates of company making revenue of 12M in the next quarter. Company posted 10.89M and 13.79M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -43.41% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 2.61% while estimates for its earnings growth in next 5 years are of 4.49%.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders

Insiders are in possession of 3.50% of company’s total shares while institution are holding 68.96 percent of that, with stock having share float percentage of 71.47%. Investors also watch the number of corporate investors in a company very closely, which is 68.96% institutions for Recursion Pharmaceuticals Inc that are currently holding shares of the company. ARK INVESTMENT MANAGEMENT LLC is the top institutional holder at RXRX for having 28.14 million shares of worth $211.07 million. And as of 2024-06-30, it was holding 11.924 of the company’s outstanding shares.

The second largest institutional holder is BAILLIE GIFFORD & CO, which was holding about 26.59 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.266 of outstanding shares, having a total worth of $199.42 million.

On the other hand, ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 19.4 shares of worth $138.91 million or 5.06% of the total outstanding shares. The later fund manager was in possession of 12.54 shares on Nov 30, 2024 , making its stake of worth around $89.75 million in the company or a holder of 3.27% of company’s stock.